Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner

Albumin as a versatile platform for drug half-life extension

(2013) Darrell Sleep et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor

(2012) Jan Terje Andersen et al.   Nature Communications

Liraglutide: the therapeutic promise from animal models

(2010) L. B. Knudsen   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain

(2010) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The production, characterisation and enhanced pharmacokinetics of scFv–albumin fusions expressed in Saccharomyces cerevisiae

(2010) Leslie Evans et al.   PROTEIN EXPRESSION AND PURIFICATION

The Versatile MHC Class I-related FcRn Protects IgG and Albumin from Degradation: Implications for Development of New Diagnostics and Therapeutics

(2009) Jan Terje Andersen et al.   Drug Metabolism and Pharmacokinetics

Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding

(2009) Jan Terje Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Modulation of Chaperone Gene Expression in Mutagenized Saccharomyces cerevisiae Strains Developed for Recombinant Human Albumin Production Results in Increased Production of Multiple Heterologous Proteins

(2008) T. Payne et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Discovering and improving novel peptide therapeutics

(2008) D MCGREGOR   CURRENT OPINION IN PHARMACOLOGY

Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues

(2008) Jan T. Andersen et al.   FEBS Journal

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

(2008) L. J. Holt et al.   PROTEIN ENGINEERING DESIGN & SELECTION